Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (161-170 of 336) with videos related to

Pageof 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS LymphomaAgnieszka Korfel, Uwe Schlegel, Ulrich Herrlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!Agnieszka Korfel, Marc Chamberlain, Ed Neuwelt, et al.
Leukemia & Lymphoma|July 7, 2007
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Rudolf Weide, Georg Hess, Hubert Köppler, et al.
British Journal of Haematology|October 23, 2024
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL NetworkLinmiao Jiang, Martin Dreyling, Olivier Hermine, et al.
Leukemia & Lymphoma|July 8, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysisJames J Wu, Sally W Wade, Taha Itani, et al.
Blood Advances|February 21, 2025
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphomaKatja Gutmair, Diego Villa, Nicholas Cunningham, et al.
Hemasphere|April 20, 2022
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-upMartin Dreyling, Andre Goy, Georg Hess, et al.
Blood|December 14, 2007
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupOlaf Determann, Eva Hoster, German Ott, et al.
Haematologica|July 2, 2013
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working PartySilvia Montoto, Paolo Corradini, Martin Dreyling, et al.
Future Oncology (London, England)|September 28, 2020
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphomaMartin Dreyling, Constantine S Tam, Michael Wang, et al.
Pageof 34

Showing results (161-170 of 336) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS LymphomaAgnieszka Korfel, Uwe Schlegel, Ulrich Herrlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!Agnieszka Korfel, Marc Chamberlain, Ed Neuwelt, et al.
Leukemia & Lymphoma|July 7, 2007
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Rudolf Weide, Georg Hess, Hubert Köppler, et al.
British Journal of Haematology|October 23, 2024
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL NetworkLinmiao Jiang, Martin Dreyling, Olivier Hermine, et al.
Leukemia & Lymphoma|July 8, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysisJames J Wu, Sally W Wade, Taha Itani, et al.
Blood Advances|February 21, 2025
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphomaKatja Gutmair, Diego Villa, Nicholas Cunningham, et al.
Hemasphere|April 20, 2022
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-upMartin Dreyling, Andre Goy, Georg Hess, et al.
Blood|December 14, 2007
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupOlaf Determann, Eva Hoster, German Ott, et al.
Haematologica|July 2, 2013
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working PartySilvia Montoto, Paolo Corradini, Martin Dreyling, et al.
Future Oncology (London, England)|September 28, 2020
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphomaMartin Dreyling, Constantine S Tam, Michael Wang, et al.
Pageof 34